In the pharmaceutical industry, ghostwriting has been a major problem in recent years, and it could end up in the hands of lawyers. False claims Act lawsuits could force the industry to stop paying ghostwriters for scientific research. Drug companies are likely to state slanted risk-benefit ratios on their new drug applications. If the product is found ineffective or unsafe, federal money could have been falsely obtained. This situation would make ghostwriting illegal.